<DOC>
	<DOCNO>NCT01926769</DOCNO>
	<brief_summary>To determine safety efficacy second-line treatment Metformin Chemotherapy ( FOLFOX6 FOFIRI ) second line treatment advance colorectal cancer</brief_summary>
	<brief_title>A Phase II Study Determine Safety Efficacy Second-line Treatment With Metformin Chemotherapy ( FOLFOX6 FOFIRI ) Second Line Threatment Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>age 18 histologically confirmted advanced colorectal cancer ECOG PS 02 expect life span 3months normal bone marrow , liver , renal function 5FU , oxaliplatin , irinotecan Metformin Allergic history Lactic acidosis , metabolic acidosis active infection severe neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metformin</keyword>
	<keyword>FOLFOX6</keyword>
	<keyword>FOFIRI</keyword>
	<keyword>5FU</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>